@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce
> Daiichi Sankyo has acquired ImCo, a growing mail-order OTC drug and cosmetics maker. Report
> Mylan ($MYL), bending to pressure, has agreed like many other drugmakers to write contracts that prevent distributors from selling its drug rocuronium bromide for use in lethal injections. Story
> The maker of the first liquid dose aspirin is looking for a partner. Report
> French vaccine maker Abivax is conducting clinical trials on a hepatitis C vaccined developed in Cuba. Story
Medical Device News
@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce
> Google sees independent startups as key to new Alphabet reorganization. Report
> NIH's BRAIN initiative, philanthropic Kavli Foundation provide $185M to study brain science. More
> Siemens nabs Abbott SVP to run healthcare in North America. Article
Biotech News
@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech
@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce
@DamianFierce: Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce
> XenoPort hits reset after a psoriasis setback, cutting jobs and bailing on R&D. Report
> Regeneron inks a $325M deal, selling Asian rights to a pain treatment. Story
> Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug. Article